TLR2 and myeloid sarcoma: These measurements revealed that TLR2-stimulant activities were far greater in urine samples of MS patients compared to HC (1.72, 126.2, and 55.5 ng/ml), relative to Pam3CSK4-equivalent activity, for HC, MS relapse, and MS remission, respectively [P = 0.0004, P = 0.0020 (Figures 4A,B)].